Biothera Completes Enrollment of Second Phase 2b Lung Cancer Trial
3/13/2013 9:03:27 AM
More...
|
Dr. John Atkinson Joins Biothera Research Advisory Board
1/4/2013 6:09:36 AM
More...
|
Biothera Release: Imprime PGG in Combination With Monoclonal Antibody Therapy Achieves 64% Complete Response Rate in Chronic Lymphocytic Leukemia Patients
12/10/2012 10:14:48 AM
More...
|
Sanguine Corporation (SGNC) Appoints Darlene Rosario, Vice President of Regulatory Affairs & Quality at Biothera, to Clinical Advisory Board and Ethics Committee
11/7/2012 10:30:50 AM
More...
|
Biothera Names Patricia Molloy, M.D., Chief Medical Officer
11/21/2011 9:12:07 AM
More...
|
Biothera Phase II Lung Cancer Trial Fully Enrolled
11/17/2011 7:19:25 AM
More...
|
Biothera's Imprime PGG(R) Improves Survival in KRAS Mutant Colorectal Cancer Patients
6/23/2011 9:24:03 AM
More...
|
Biothera Phase II Lung Cancer Trials Achieve Stage 1 Goals
4/19/2011 10:17:01 AM
More...
|
Biothera to Present Research Results at European Society for Medical Oncology World Gastrointestinal Congress
4/19/2011 10:16:17 AM
More...
|
Phase I/II Clinical Trial in Chronic Lymphocytic Leukemia to Evaluate Combination Therapy with Biothera’s Imprime PGG
3/14/2011 10:51:00 AM
More...
|
|